S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.02 (+2.22%)
NVDA   466.99 (+0.29%)
NIO   7.92 (+6.59%)
BABA   72.44 (+0.08%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.82 (+2.08%)
MU   74.26 (+0.77%)
CGC   0.72 (+8.09%)
GE   121.82 (+1.32%)
DIS   91.24 (+0.50%)
AMC   7.12 (+1.42%)
PFE   29.16 (+0.24%)
PYPL   58.77 (+1.47%)
XOM   100.55 (+0.11%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.02 (+2.22%)
NVDA   466.99 (+0.29%)
NIO   7.92 (+6.59%)
BABA   72.44 (+0.08%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.82 (+2.08%)
MU   74.26 (+0.77%)
CGC   0.72 (+8.09%)
GE   121.82 (+1.32%)
DIS   91.24 (+0.50%)
AMC   7.12 (+1.42%)
PFE   29.16 (+0.24%)
PYPL   58.77 (+1.47%)
XOM   100.55 (+0.11%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.02 (+2.22%)
NVDA   466.99 (+0.29%)
NIO   7.92 (+6.59%)
BABA   72.44 (+0.08%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.82 (+2.08%)
MU   74.26 (+0.77%)
CGC   0.72 (+8.09%)
GE   121.82 (+1.32%)
DIS   91.24 (+0.50%)
AMC   7.12 (+1.42%)
PFE   29.16 (+0.24%)
PYPL   58.77 (+1.47%)
XOM   100.55 (+0.11%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.02 (+2.22%)
NVDA   466.99 (+0.29%)
NIO   7.92 (+6.59%)
BABA   72.44 (+0.08%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.82 (+2.08%)
MU   74.26 (+0.77%)
CGC   0.72 (+8.09%)
GE   121.82 (+1.32%)
DIS   91.24 (+0.50%)
AMC   7.12 (+1.42%)
PFE   29.16 (+0.24%)
PYPL   58.77 (+1.47%)
XOM   100.55 (+0.11%)

Century Therapeutics Stock Price, News & Analysis (NASDAQ:IPSC)

$1.71
+0.13 (+8.23%)
(As of 10:01 AM ET)
Compare
Today's Range
$1.60
$1.75
50-Day Range
$1.28
$2.02
52-Week Range
$1.28
$9.71
Volume
302,626 shs
Average Volume
136,682 shs
Market Capitalization
$102.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.57

Century Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
748.2% Upside
$13.57 Price Target
Short Interest
Healthy
3.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Century Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.08) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

349th out of 948 stocks

Biological Products, Except Diagnostic Industry

52nd out of 147 stocks


IPSC stock logo

About Century Therapeutics Stock (NASDAQ:IPSC)

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Stock Price History

IPSC Stock News Headlines

Century Therapeutics Announces IND Application Clearance For CNTY-101
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
FMR LLC Adjusts Position in Century Therapeutics Inc
William Blair Reaffirms Their Hold Rating on Century Therapeutics (IPSC)
Recap: Century Therapeutics Q3 Earnings
Century Therapeutics Inc.
See More Headlines
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.57
High Stock Price Target
$20.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+759.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-130,930,000.00
Net Margins
-5,183.16%
Pretax Margin
-5,071.34%

Debt

Sales & Book Value

Annual Sales
$2.49 million
Book Value
$5.13 per share

Miscellaneous

Free Float
55,288,000
Market Cap
$94.54 million
Optionable
Not Optionable
Beta
0.67
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Michael C. Diem M.D. (Age 52)
    Chief Financial Officer
    Comp: $650.66k
  • Dr. Adrienne Farid Ph.D. (Age 61)
    COO & Head of Early Development
    Comp: $650.66k
  • Dr. Gregory Russotti Ph.D. (Age 56)
    Interim President & CEO
  • Mr. Kenneth J. Dow J.D.
    Senior VP of General Counsel
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Hyam I. Levitsky M.D. (Age 65)
    President of Research & Development
    Comp: $502.12k
  • Michael Naso Ph.D.
    Senior VP of Cell Engineering
  • Mr. Douglas Carr CPA
    Senior VP of Finance & Operations and Secretary














IPSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price target for 2024?

6 analysts have issued 12-month price targets for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $20.00. On average, they expect the company's stock price to reach $13.57 in the next twelve months. This suggests a possible upside of 759.0% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2023?

Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC shares have decreased by 69.2% and is now trading at $1.58.
View the best growth stocks for 2023 here
.

Are investors shorting Century Therapeutics?

Century Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 742,600 shares, a decrease of 11.9% from the October 31st total of 842,900 shares. Based on an average daily volume of 128,900 shares, the days-to-cover ratio is presently 5.8 days. Approximately 3.1% of the company's stock are short sold.
View Century Therapeutics' Short Interest
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The business had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.08 million. Century Therapeutics had a negative trailing twelve-month return on equity of 49.28% and a negative net margin of 5,183.16%.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.56%), Avidity Partners Management LP (1.84%), Jacobs Levy Equity Management Inc. (0.29%), Charles Schwab Investment Management Inc. (0.25%), New York Life Investment Management LLC (0.17%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends
.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IPSC) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -